Table 1.

Dynamics of laboratory tests, key highlights, and treatment.

Patient's age	TC	LDL-C	TG	HDL-C	Alb	Cr	24 hUP	Key highlights
(date: dd/mm/yyyy)	(2.80–5.70 mmol/L)	(2.7–3.1 mmol/L)	(0.29–1.83 mmol/L)	(1.16–1.55 mmol/L)	(40–55 g/L)	(53–115 μmol/L)	(<0.15 g/24 h)	and treatment
13y (10-12-2019)	14.16	12.36	1.47	0.76	31	39	-	Genetic screening and renal biopsy were conducted in our hospital. Treatment with atorvastatin (30 mg/day), ezetimibe (10 mg/day) and benazepril (10 mg/day) were started. Administration of PCSK9 inhibitor evolocumab (420 mg/month) was started 1 month after discharge.
13y (27-12-2019)	13.03	9.84	1.82	1.09	34	36	2.08
14y (06-06-2020)	8.55	6.14	1.11	1.85	66	25	-	Rosuvastatin (10 mg/day) was used to replace atorvastatin.
14y (07-09-2020)	13.05	10.2	1.03	2.15	69.9	26	0.01	Patient discontinued rosuvastatin (10 mg/day) and benazepril was stopped.
14y (04-12-2020)	7.36	5.36	1.12	1.57	70.8	33	0.01	15 mg atorvastatin was administered daily.
15y (06-03-2021)	6.36	4.81	0.94	1.22	42.9	-	0.08	Medication is composed of atorvastatin (15 mg/day), ezetimibe (10 mg/day), PCSK9 inhibitor evolocumab (420 mg/month).
15y (18-09-2021)	6.29	4.63	0.60	1.25	44.5	41.90	-

Exact dates of the clinic visits and drug administration were recorded. 24 hUP, 24-h urinary protein; Alb, albumin; Cr, creatinine. To convert total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) from millimoles per liter to milligrams per deciliter, the value was divided by 38.67. To convert triglycerides (TGs) from millimoles per liter to milligrams per deciliter, the value was divided by 88.